Opioid Litigation: Drug Mfrs. Lose Bid To Limit Data Disclosure; First Trials Set For March
US court orders firms to release information on all opioid products ever classified as Schedule II from one year prior to launch date; government, manufacturers oppose public disclosure of DEA distribution data.
You may also be interested in...
Company is paying nearly $200m for an Oklahoma State University endowment, $12.5m to abate effects of opioid crisis and $60m for litigation costs.
Finance Watch: Panic Over FDA Commissioner's Resignation Was Short-Lived, Though IPOs Still Languish
Public Company Edition: Biotech stocks sank when US FDA Commissioner Scott Gottlieb announced his departure, but have nearly recovered to pre-resignation levels, except for newly public firms. Also, Biohaven's raises cash for PRV purchase and Endo issues $1.5bn in new debt.
Bellwether trial set to begin in September after judge says cities may be able to recover damages for cost of governmental services that are the result of defendants' alleged conduct.